Mylan Pharmaceuticals announced the launch of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first available bioequivalent alternative to ADVAIR DISKUS in Canada.
The European Medicine Agency has launched a six month consultation on the principles that will form the basis of the electronic product information (ePI)…
The U.S. Food and Drug Administration approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in...